Beta Bionics, Inc. — Director's Dealing 2025

Jan 30, 2025

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Beta Bionics, Inc. (BBNX)
CIK: 0001674632
Period of Report: 2025-01-29

Reporting Person: Mensinger Mike (N/A)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series D Preferred Stock	$		Class B Common Stock (15107)		Direct
Class B Common Stock Warrant (right to buy)	$0.02	2033-08-27	Class B Common Stock (10575)		Direct
Employee Stock Option (right to buy)	$5.10	2033-09-13	Class B Common Stock (236553)		Direct

Footnotes

F1: Each share of Series D Preferred Stock (the "Preferred Stock") is convertible into shares of Class B Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the "IPO"), the Preferred Stock will convert into the number of shares of Class B Common Stock of the Issuer shown in column 3 and subsequently into an equal number of shares of Common Stock of the Issuer. The Preferred Stock has no expiration date.

F2: In accordance with the Issuer's Amended and Restated Certificate of Incorporation, the Issuer's outstanding shares of Class B Common Stock will convert into an equal number of shares of Common Stock immediately prior to the closing of the IPO.

F3: One-fourth of the shares subject to this option shall vest one year after August 1, 2023, and thereafter 1/36th of the shares subject to this option shall vest on each monthly anniversary thereof.